Anixa Biosciences, Inc.

twitter logo
Nasdaq: ANIX
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisors
    • Breast Cancer Clinical Advisory Board
    • Cancer Business Advisory Board
  • Technologies
    • CAR-T
      • Introduction
      • Markets
      • Science
      • Collaborators
    • Cancer Vaccines
      • Introduction
      • Markets
      • Science
      • Collaborators
      • Breast Cancer Clinical Advisory Board
  • Pipeline
  • Investors
    • Overview
    • News Releases
    • The Future of Cancer Immunotherapy & Women’s Health
    • Events & Presentations
      • Events
      • Corporate Presentation
    • Stock Information
      • Quote
      • Charts
      • Historical Data
      • Analyst Coverage
    • SEC Filings
      • SEC Filings
    • Financial Reports
      • Annual Reports
      • Quarterly Reports
    • Corporate Governance
      • Governance Documents
      • Committee Charters
  • News
    • Press Releases
    • Anixa In The News
    • Publications
    • YouTube Channel
  • Contact Us

SEC Filings

Investors

Investors

  • Overview
  • News Releases
  • The Future of Cancer Immunotherapy & Women’s Health
  • Events & Presentations
    • Events
    • Corporate Presentation
  • Stock Info
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
  • Financial Reports
    • Annual Reports
    • Quarterly Reports
  • Governance
    • Governance Documents
    • Committee Charters
  • Investor Resources
    • Investor FAQs
    • Email Alerts
    • Fact Sheet
    • Contact IR
    • RSS News Feed
  • SEC Filings

  • Overview
Filter Filings:
Date Form Description Docs XBRL Pages
06/04/10 UPLOAD SEC-generated letter PDF 5
06/01/10 DFAN14A Definitive additional proxy soliciting materials filed by non-management including Rule 14(a)(12) material HTML PDF 5
05/28/10 SC 13D Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities
Related Documents
EX-99.1
EX-99.2
HTML PDF 20
05/28/10 PREC14A Preliminary proxy statement in connection with contested solicitations HTML PDF 40
05/17/10 SC 13G/A Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions HTML PDF 6
05/13/10 CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission. HTML PDF 10
04/27/10 UPLOAD SEC-generated letter PDF 3
04/12/10 CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission. HTML PDF 11
03/31/10 UPLOAD SEC-generated letter PDF 4
03/17/10 10-Q Quarterly report pursuant to sections 13 or 15(d)
Related Documents
EX-31.1
EX-31.2
EX-32.1
EX-32.2
HTML PDF 47
RSS
  • << Previous
  • 1...
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • ...96
  • Next >>

Sign up for email Updates

Be The First to Receive Breaking News

Sign Up Now
Logo Itus
twitter logo

Latest News & Events

Apr 9, 2026

Anixa Biosciences to Participate in RedChip's Biotech Resurgence: Platforms and Pipelines of Today's Innovators Conference on April 16, 2026

Read More...
Apr 7, 2026

Anixa Biosciences to Participate in Water Tower Research Insights Conference on April 14, 2026

Read More...
Apr 6, 2026

Anixa Biosciences CEO Featured on Smart Money Circle Interview Highlighting Advances in Cancer Immunotherapy Programs

Read More...
Copyrights © 2026 Anixa Biosciences, Inc.. All Rights Reserved.
twitter logo Privacy Policy Terms of Use Disclaimer Sitemap